Table 2. Characteristics of enrolled patients and univariate analysis for survival.

			First-line progression-free survival			Overall survival
Feature	N	%	Median (months)	HR (95% CI)	P-value	Median (months)	HR (95% CI)	P-value
Median age (range)	59 (23–86)			1.1 (0.8–1.6)	0.5		1.7 (1.1–2.6)	0.03
⩽65 years	113	67	12.5			43.7
>65 years	55	33	10.7			30.6
Gender				1.1 (0.8–1.5)	0.8		1.0 (0.7–1.6)	0.8
Male	87	52	11.7			38.9
Female	81	48	12.5			38.2
Stage at diagnosis
I–III	77	46	13.6	0.8 (0.6–1.1)	0.2	38.2	1.2 (0.8–1.8)	0.5
IV	91	54	11.6			35.2
Tumour location
Colon	135	80	11.3	1.8 (1.2–2.7)	0.008	33.5	2.0 (1.1–3.7)	0.02
Rectum	33	20	16.3			66.6
Number of metastatic lesions	Median: 2
1	50	30	20.5	0.4 (0.2–0.6)	<0.0001	56.8	0.4 (0.2–0.8)	0.008
2	83	49	11.7	0.8 (0.5–1.2)	0.2	34.8	0.8 (0.5–1.4)	0.4
⩾3	35	21	10.5			28.8
Number of treatment lines	Median: 3
1	43	25	44.5	0.3 (0.2–0.5)	<0.0001	35.2	1.6 (0.9–2.8)	0.1
2	47	28	11.5	0.9 (0.6–1.3)	0.7	34.8	1.4 (0.8)	0.2
⩾3	78	47	11.8			39.1
Histologic grade				1.4 (1.0–2.1)	0.06		1.8 (1.1–2.8)	0.02
I–II	127	76	12.5			41.1
III	41	24	9.4			33.7
Adjuvant treatment				1.1 (0.8–1.6)	0.6		1.0 (0.7–1.6)	0.9
Yes	58	35	13.7			38.9
No	110	65	11.7			39.1
Metastatectomy				0.4(0.2–0.6)	<0.0001		0.6 (0.3–1.2)	0.1
Yes	30	18	27.4			46.3
No	138	82	11.1			38.4
KRAS status				0.9 (0.7–1.3)	0.7		1.1 (0.7–1.8)	0.6
Mutant	62	37	12.3			35.8
WT	106	63	11.8			40.5
BRAF status				4.9 (2.7–9.0)	<0.0001		4.5 (2.4–8.4)	<0.0001
Mutant	13	8	4.3			10.9
WT	155	92	12.5			40.5
PIK3CA status				1.3 (0.8–1.9)	0.3		1.0 (0.6–1.8)	0.99
Mutant	26	15	11.4			44.7
WT	142	85	12.1			38.2

HR=hazard ratio; WT=wild type.